Supply Woes Plague All 7 New Biosimilar Ingredients Listed since 2023
To read the full story
Related Article
- Celltrion to Lift Shipment Curbs on Japan’s 1st Actemra Biosimilar
November 9, 2026
- Fuji Pharma Recalls Eylea Biosimilar Lots over Faulty Finger Grips
November 6, 2026
- Mochida Lifts G-Lasta Biosimilar Shipment Curbs after Over 2 Years
November 4, 2026
- Japan’s 1st Xolair Biosimilar Finally Set for December Launch after Delays
October 23, 2026
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
- Japan’s First Stelara Biosimilar to Skip November Listing on Risk of Import Delays: Fuji Pharma
November 14, 2023
COMMENTARY
- Supply Woes Plague All 7 New Biosimilar Ingredients Listed since 2023
November 16, 2026
- Japan Drug Wholesalers Caught in Multiple Dilemmas as Price Gap Narrows
November 10, 2026
- Deeper CEA Price Cuts Demand More Than a “Certain Degree of Validity”
November 2, 2026
- Alzheimer’s Pipeline Looks Past Amyloid to Earlier Intervention, Tau Targets
October 28, 2026
- Lp(a) Drugs Face Next Test in Quest to Cut Cardiovascular Risk
October 19, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





